The association of low bone mineral density with systemic inflammation in clinically stable COPD

Endocrine

Volumn 42, Issue 1, 2012, Pages 190-195

  Liang, Binmiao ^a   Feng, Yulin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Bone mineral density; Chronic obstructive pulmonary disease; Inflammation; Osteoporosis

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BONE DENSITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 84865022359     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9583-x     Document Type: Article

References (36)

1. K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, J. Zielinski, Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532-555 (2007)
2. D.D. Sin, N.R. Anthonisen, J.B. Soriano, A.G. Agusti, Mortality in COPD: role of comorbidities. Eur. Respir. J. 28, 1245-1257 (2006)
3. L. Graat-Verboom, E.F. Wouters, F.W. Smeenk, B.E. Van Den Borne, R. Lunde, M.A. Spruit, Current status of research on osteoporosis in COPD: a systematic review. Eur. Respir. J. 34, 209-218 (2009)
4. C.E. Bolton, A.A. Ionescu, K.M. Shiels, R.J. Pettit, P.H. Edwards, M.D. Stone, L.S. Nixon, W.D. Evans, T.L. Griffiths, D.J. Shale, Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170, 1286-1293 (2004)
5. F. de Vries, T.P. van Staa, M.S. Bracke, C. Cooper, H.G. Leufkens, J.W. Lammers, Severity of obstructive airway disease and risk of osteoporotic fracture. Eur. Respir. J. 25, 879-884 (2005)
6. N.E. Lane, Therapy insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2, 562-569 (2006)
7. T. Ali, D. Lam, M.S. Bronze, M.B. Humphrey, Osteoporosis in inflammatory bowel disease. Am. J. Med. 122, 599-604 (2009)
8. P.G. Lacativa, M.L. Farias, Osteoporosis and inflammation. Arq. Bras. Endocrinol. Metabol. 54, 123-132 (2010)
9. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi, J. Wanger, ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 26, 319-338 (2005)
10. L.P. Boulet, A. Becker, D. Berube, R. Beveridge, P. Ernst, Canadian asthma consensus report, 1999. Can. Med. Assoc. J. 161, S1-S61 (1999)
11. N.H. Li, P.Z. Qu, H.M. Zhu, D.Z. Yang, R. Zheng, E.Y. Liao, Normal references for standardization of bone mineral density in health population of multi-center in China. Chin. J. Gerontol. 22, 3-5 (2002)
12. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization Technical Report Series no 843, pp 1-129 (1994)
13. P.D. Scanlon, J.E. Connett, R.A. Wise, D.P. Tashkin, T. Madhok, M. Skeans, P.C. Carpenter, W.C. Bailey, A.S. Buist, M. Eichenhorn, R.E. Kanner, G. Weinmann, Lung health study research group, loss of bone density with inhaled triamcinolone in lung health study II. Am. J. Respir. Crit. Care Med. 170, 1302-1309 (2004)
14. A. Kjensli, P. Mowinckel, M.S. Ryg, J.A. Falch, Low bone mineral density is related to severity of chronic obstructive pulmonary disease. Bone 40, 493-497 (2007)
15. A. Vrieze, M.H. de Greef, P.J. Wijkstra, J.B. Wempe, Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos. Int. 18, 1197-1202 (2007)
16. R. Broekhuizen, E.F. Wouters, E.C. Creutzberg, A.M. Schols, Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61, 17-22 (2006)
17. E.F. Dubois, E. Roder, P.N. Dekhuijzen, A.E. Zwinderman, D.H. Schweitzer, Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. Chest 121, 1456-1463 (2002)
18. P. Vestergaard, L. Rejnmark, L. Mosekilde, Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 132, 1599-1607 (2007)
19. T.P. van Staa, B. Leufkens, C. Cooper, Bone loss and inhaled glucocorticoids. N. Engl. J. Med. 346, 533-535 (2002)
20. E. Lau, M. Mamdani, K. Tu, Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am. J. Med. 114, 142-145 (2003)
21. T.P. van Staa, H.G. Leufkens, C. Cooper, Inhaled corticosteroids and hip fracture: disease or drugs? Am. J. Respir. Crit. Care Med. 168, 128-129 (2003)
22. M.J. Sevenoaks, R.A. Stockley, Chronic obstructive pulmonary disease, inflammation and co-morbidity-a common inflammatory phenotype? Respir. Res. 7, 70 (2006)
23. P.J. Barnes, B.R. Celli, Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 33, 1165-1185 (2009)
24. A. Huertas, P. Palange, COPD: a multifactorial systemic disease. Ther. Adv. Respir. Dis. 5, 217-224 (2011)
25. W.Q. Gan, S.F. Man, A. Senthilselvan, D.D. Sin, Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59, 574-580 (2004)
26. S.L. Teitelbaum, Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170, 427-435 (2007)
27. R. Sabit, C.E. Bolton, P.H. Edwards, R.J. Pettit, W.D. Evans, C.M. McEniery, I.B. Wilkinson, J.R. Cockcroft, D.J. Shale, Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 1259-1265 (2007)
28. W. Gianni, A. Ricci, P. Gazzaniga, M. Brama, M. Pietropaolo, S. Votano, F. Patanè, A.M. Aglianò, G. Spera, V. Marigliano, S. Ammendola, D. Agnusdei, S. Migliaccio, R. Scandurra, Raloxifene modulates interleukin-6 and tumor necrosis factoralpha synthesis in vivo: results from a pilot clinical study. J. Clin. Endocrinol. Metab. 89, 6097-6099 (2004)
29. L.M. Fabbri, K.F. Rabe, From COPD to chronic systemic inflammatory syndrome? Lancet 370, 797-799 (2007)
30. E. Küpeli, G. Ulubay, S.S. Ulasli, T. Sahin, Z. Erayman, A. Gürsoy, Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 38, 76-82 (2010)
31. T. Yamaguchi, Osteoporosis associated with the metabolic syndrome. Clin. Calcium 18, 606-611 (2008)
32. H.Y. Kim, J.W. Choe, H.K. Kim, S.J. Bae, B.J. Kim, S.H. Lee, J.M. Koh, K.O. Han, H.M. Park, G.S. Kim, Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. Calcif. Tissue Int. 86, 350-358 (2010)
33. M.S. Nanes, Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321, 1-15 (2003)
34. M. Malerba, S. Bossoni, A. Radaeli, E. Mori, S. Bonadonna, A. Giustina, C. Tantucci, Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest 127, 515-521 (2005)
35. M. Malerba, S. Bossoni, A. Radaeli, E. Mori, G. Romanelli, C. Tantucci, A. Giustina, V. Grassi, Bone ultrasonometric features and growth hormone secretion in asthmatic patients during chronic inhaled corticosteroid therapy. Bone 38, 119-124 (2006)
36. G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877-884 (2010)